FACULTY COMMENTS
DR LONIAL: The Chanan-Khan paper was a multicenter, retrospective
analysis evaluating the ability to use bortezomib in
patients with hemodialysis-dependent renal failure.
It reassures us that the response rates are good. The toxicity associated with bortezomib in the setting of hemodialysis was not worse than one would have expected in a similarly heavily pretreated patient population.
Bortezomib is probably one of the first drugs you want to use in patients with renal dysfunction. If the renal dysfunction is related to myeloma, you have a good chance of reversing it.
DR JAKUBOWIAK: This study puts a stamp on what we already
know — namely, we don’t have to be worried about renal insufficiency
for patients who will be treated with bortezomib-based
regimens. The response rates and toxicities are in the same
range, regardless of renal functioning.
| Table of Contents | Top of Page |
